TY - JOUR
T1 - Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis
AU - Oh, Jiwon
AU - O'Connor, Paul W.
N1 - Publisher Copyright:
© 2015 Wolters Kluwer Health, Inc.
PY - 2015/6/6
Y1 - 2015/6/6
N2 - To summarize mechanisms of action, efficacy, and safety of novel and imminently emerging disease-modifying treatments (DMTs) intended to be used in relapsing-remitting multiple sclerosis (RRMS). Recent findings Novel and imminently emerging DMTs for the treatment of RRMS include alemtuzumab, daclizumab, ocrelizumab, pegylated interferon-β-1a, and three times weekly glatiramer acetate. These DMTs have substantially different mechanisms of action, efficacy, and safety and tolerability profiles, which are summarized concisely in this article. Summary The treatment landscape of RRMS is evolving rapidly as the available treatment options have doubled in recent years, and a number of novel DMTs will likely become available in the near future. Choosing the optimal DMT for patients is becoming an increasingly complex process, and the care of patients with MS will likely require regular input from neurologists subspecializing in the care of patients with MS. As the use of novel DMTs with unknown long-term safety profiles increases, postmarketing surveillance and vigilance with regards to safety monitoring will be essential to confirm the safety and clinical efficacy of these DMTs for patients with RRMS.
AB - To summarize mechanisms of action, efficacy, and safety of novel and imminently emerging disease-modifying treatments (DMTs) intended to be used in relapsing-remitting multiple sclerosis (RRMS). Recent findings Novel and imminently emerging DMTs for the treatment of RRMS include alemtuzumab, daclizumab, ocrelizumab, pegylated interferon-β-1a, and three times weekly glatiramer acetate. These DMTs have substantially different mechanisms of action, efficacy, and safety and tolerability profiles, which are summarized concisely in this article. Summary The treatment landscape of RRMS is evolving rapidly as the available treatment options have doubled in recent years, and a number of novel DMTs will likely become available in the near future. Choosing the optimal DMT for patients is becoming an increasingly complex process, and the care of patients with MS will likely require regular input from neurologists subspecializing in the care of patients with MS. As the use of novel DMTs with unknown long-term safety profiles increases, postmarketing surveillance and vigilance with regards to safety monitoring will be essential to confirm the safety and clinical efficacy of these DMTs for patients with RRMS.
KW - Efficacy
KW - novel and imminently emerging disease-modifying treatments
KW - relapsing-remitting multiple sclerosis
KW - safety and tolerability
UR - http://www.scopus.com/inward/record.url?scp=84929470428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929470428&partnerID=8YFLogxK
U2 - 10.1097/WCO.0000000000000203
DO - 10.1097/WCO.0000000000000203
M3 - Review article
C2 - 25887773
AN - SCOPUS:84929470428
SN - 1350-7540
VL - 28
SP - 230
EP - 236
JO - Current opinion in neurology
JF - Current opinion in neurology
IS - 3
ER -